SGK3 and neoplasm: To investigate whether SGK3 could be a potential therapeutic target if resistance to alpelisib had been developed, MCF7R and T47DR cells with or without SGK3 manipulation were orthotopically injected into the mouse mammary fat pads and BYL719 treatment was given when the tumor volume reached about 100mm3.